↓ Skip to main content

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG Interferon-α–Based Regimens

Overview of attention for article published in Clinical Pharmacology & Therapeutics, October 2013
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (82nd percentile)
  • High Attention Score compared to outputs of the same age and source (82nd percentile)

Mentioned by

twitter
8 tweeters
wikipedia
1 Wikipedia page

Citations

dimensions_citation
57 Dimensions

Readers on

mendeley
80 Mendeley
Title
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG Interferon-α–Based Regimens
Published in
Clinical Pharmacology & Therapeutics, October 2013
DOI 10.1038/clpt.2013.203
Pubmed ID
Authors

A J Muir, L Gong, S G Johnson, M T M Lee, M S Williams, T E Klein, K E Caudle, D R Nelson

Abstract

Pegylated interferon-α (PEG-IFN-α or PEG-IFN 2a and 2b)- and ribavirin (RBV)-based regimens are the mainstay for treatment of hepatitis C virus (HCV) genotype 1. IFNL3 (IL28B) genotype is the strongest baseline predictor of response to PEG-IFN-α and RBV therapy in previously untreated patients and can be used by patients and clinicians as part of the shared decision-making process for initiating treatment for HCV infection. We provide information regarding the clinical use of PEG-IFN-α- and RBV-containing regimens based on IFNL3 genotype.

Twitter Demographics

The data shown below were collected from the profiles of 8 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 80 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
India 1 1%
France 1 1%
Argentina 1 1%
Egypt 1 1%
Unknown 76 95%

Demographic breakdown

Readers by professional status Count As %
Student > Master 18 23%
Researcher 13 16%
Student > Ph. D. Student 13 16%
Student > Postgraduate 7 9%
Other 5 6%
Other 18 23%
Unknown 6 8%
Readers by discipline Count As %
Medicine and Dentistry 23 29%
Agricultural and Biological Sciences 14 18%
Biochemistry, Genetics and Molecular Biology 13 16%
Pharmacology, Toxicology and Pharmaceutical Science 10 13%
Chemistry 2 3%
Other 8 10%
Unknown 10 13%

Attention Score in Context

This research output has an Altmetric Attention Score of 8. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 November 2018.
All research outputs
#3,062,457
of 18,141,016 outputs
Outputs from Clinical Pharmacology & Therapeutics
#631
of 3,721 outputs
Outputs of similar age
#33,620
of 196,377 outputs
Outputs of similar age from Clinical Pharmacology & Therapeutics
#6
of 28 outputs
Altmetric has tracked 18,141,016 research outputs across all sources so far. Compared to these this one has done well and is in the 83rd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,721 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.0. This one has done well, scoring higher than 82% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 196,377 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 82% of its contemporaries.
We're also able to compare this research output to 28 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 82% of its contemporaries.